PMID- 35247475 OWN - NLM STAT- MEDLINE DCOM- 20220419 LR - 20220419 IS - 1872-7573 (Electronic) IS - 0378-8741 (Linking) VI - 292 DP - 2022 Jun 28 TI - The Chinese medicine Fufang Zhenzhu Tiaozhi capsule protects against renal injury and inflammation in mice with diabetic kidney disease. PG - 115165 LID - S0378-8741(22)00203-3 [pii] LID - 10.1016/j.jep.2022.115165 [doi] AB - ETHNOPHARMACOLOGICAL RELEVANCE: Fufang Zhenzhu Tiaozhi capsule (FTZ) is a patented preparation of Chinese herbal medicine that has been used to treat hyperlipidemia, nonalcoholic fatty liver disease, atherosclerosis, and other glucolipid metabolic diseases (GLMDs) in the clinic for almost 10 years. However, how FTZ reduces albuminuria and attenuates diabetic kidney disease (DKD) progression is unknown. AIM OF THE STUDY: To clarify the effects of FTZ on DKD mice model and to explore the underlying mechanisms. MATERIALS AND METHODS: We used streptozotocin (STZ) (40 mg/kg/d, i.p. for 5 days, consecutively) combined with a high-fat diet (HFD) to induce a DKD mouse model, followed by FTZ (1, 2 g/kg/d, i.g.) treatment for 12 weeks. Losartan (30 mg/kg/d, i.g.) was used as a positive control. Measurements of 24 h proteinuria, serum creatinine (SCr), fasting blood glucose (FBG), total cholesterol (TC), triglyceride (TG), and low density lipoprotein cholesterol (LDL-C) levels and expression levels of fibronectin (FN), collagen IV, inflammatory cytokines, inflammatory cells, interleukin-17A (IL-17A) and the nuclear transcription factor-kappaB (NF-kappaB) signaling pathway in the kidney were examined. RESULTS: FTZ effectively decreased 24 h proteinuria, Scr, FBG, TC, TG, and LDL-C levels, inhibited mesangial cell expansion, reduced FN and collagen IV accumulation, and F4/80(+) macrophage cell infiltration and Ly-6G(+) neutrophil infiltration in glomerulus and tubulointerstitium. Furthermore, IL-17A production and the NF-kappaB signaling pathway were also downregulated after the administration of FTZ. CONCLUSION: FTZ might attenuate DKD progression, and inhibited kidney inflammation and fibrosis by inhibiting the expression of RORgammaT and IL-17A in vivo, offering novel insights for the clinical application of FTZ. CI - Copyright (c) 2022 Elsevier B.V. All rights reserved. FAU - Yang, Yi-Qi AU - Yang YQ AD - Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine, Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education of China, Institute of Chinese Medicine, Guangdong Pharmaceutical University, Guangdong TCM Key Laboratory for Metabolic Diseases, Guangzhou, 510006, China. Electronic address: yangyiqi2011@163.com. FAU - Tan, Hai-Bo AU - Tan HB AD - Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine, Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education of China, Institute of Chinese Medicine, Guangdong Pharmaceutical University, Guangdong TCM Key Laboratory for Metabolic Diseases, Guangzhou, 510006, China. Electronic address: thb13265042784@163.com. FAU - Zhang, Xiao-Yu AU - Zhang XY AD - Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine, Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education of China, Institute of Chinese Medicine, Guangdong Pharmaceutical University, Guangdong TCM Key Laboratory for Metabolic Diseases, Guangzhou, 510006, China. Electronic address: 493452494@qq.com. FAU - Zhang, Yu-Zhen AU - Zhang YZ AD - Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine, Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education of China, Institute of Chinese Medicine, Guangdong Pharmaceutical University, Guangdong TCM Key Laboratory for Metabolic Diseases, Guangzhou, 510006, China. Electronic address: zyz18838198112@163.com. FAU - Lin, Quan-You AU - Lin QY AD - Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine, Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education of China, Institute of Chinese Medicine, Guangdong Pharmaceutical University, Guangdong TCM Key Laboratory for Metabolic Diseases, Guangzhou, 510006, China. Electronic address: 1227487249@qq.com. FAU - Huang, Min-Yi AU - Huang MY AD - Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine, Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education of China, Institute of Chinese Medicine, Guangdong Pharmaceutical University, Guangdong TCM Key Laboratory for Metabolic Diseases, Guangzhou, 510006, China. Electronic address: hmy1121845388@163.com. FAU - Lin, Zi-Yang AU - Lin ZY AD - Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine, Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education of China, Institute of Chinese Medicine, Guangdong Pharmaceutical University, Guangdong TCM Key Laboratory for Metabolic Diseases, Guangzhou, 510006, China. Electronic address: 1061025412@qq.com. FAU - Mo, Jia-Zhi AU - Mo JZ AD - Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine, Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education of China, Institute of Chinese Medicine, Guangdong Pharmaceutical University, Guangdong TCM Key Laboratory for Metabolic Diseases, Guangzhou, 510006, China. Electronic address: mojiazhi123456@163.com. FAU - Zhang, Yue AU - Zhang Y AD - Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine, Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education of China, Institute of Chinese Medicine, Guangdong Pharmaceutical University, Guangdong TCM Key Laboratory for Metabolic Diseases, Guangzhou, 510006, China. Electronic address: zhangyuee012345@163.com. FAU - Lan, Tian AU - Lan T AD - Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine, Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education of China, Institute of Chinese Medicine, Guangdong Pharmaceutical University, Guangdong TCM Key Laboratory for Metabolic Diseases, Guangzhou, 510006, China. Electronic address: lantian@gdpu.edu.cn. FAU - Bei, Wei-Jian AU - Bei WJ AD - Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine, Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education of China, Institute of Chinese Medicine, Guangdong Pharmaceutical University, Guangdong TCM Key Laboratory for Metabolic Diseases, Guangzhou, 510006, China. Electronic address: 806362747@139.com. FAU - Guo, Jiao AU - Guo J AD - Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine, Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education of China, Institute of Chinese Medicine, Guangdong Pharmaceutical University, Guangdong TCM Key Laboratory for Metabolic Diseases, Guangzhou, 510006, China. Electronic address: gyguoyz@163.com. LA - eng PT - Journal Article DEP - 20220303 PL - Ireland TA - J Ethnopharmacol JT - Journal of ethnopharmacology JID - 7903310 RN - 0 (Cholesterol, LDL) RN - 0 (Drugs, Chinese Herbal) RN - 0 (Interleukin-17) RN - 0 (NF-kappa B) RN - 9007-34-5 (Collagen) SB - IM MH - Animals MH - Cholesterol, LDL MH - Collagen MH - *Diabetes Mellitus/drug therapy MH - *Diabetic Nephropathies/drug therapy MH - *Drugs, Chinese Herbal/pharmacology/therapeutic use MH - Female MH - Humans MH - Inflammation/drug therapy MH - Interleukin-17 MH - Kidney MH - Male MH - Medicine, Chinese Traditional MH - Mice MH - NF-kappa B MH - Proteinuria/drug therapy OTO - NOTNLM OT - Chinese medicine OT - Diabetic kidney disease OT - Inflammation EDAT- 2022/03/06 06:00 MHDA- 2022/04/20 06:00 CRDT- 2022/03/05 20:12 PHST- 2021/10/22 00:00 [received] PHST- 2022/02/14 00:00 [revised] PHST- 2022/02/28 00:00 [accepted] PHST- 2022/03/06 06:00 [pubmed] PHST- 2022/04/20 06:00 [medline] PHST- 2022/03/05 20:12 [entrez] AID - S0378-8741(22)00203-3 [pii] AID - 10.1016/j.jep.2022.115165 [doi] PST - ppublish SO - J Ethnopharmacol. 2022 Jun 28;292:115165. doi: 10.1016/j.jep.2022.115165. Epub 2022 Mar 3.